Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Change in Accured Expenses (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Change in Accured Expenses for 13 consecutive years, with -$348000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 237.55% to -$348000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 million, a 83.97% decrease, with the full-year FY2025 number at -$1.1 million, down 83.97% from a year prior.
  • Change in Accured Expenses was -$348000.0 for Q4 2025 at Ekso Bionics Holdings, down from -$38000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $568000.0 in Q3 2022 to a low of -$723000.0 in Q1 2024.
  • A 5-year average of -$82650.0 and a median of -$104500.0 in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: tumbled 3250.0% in 2022, then skyrocketed 431.51% in 2023.
  • Ekso Bionics Holdings' Change in Accured Expenses stood at $449000.0 in 2021, then tumbled by 83.74% to $73000.0 in 2022, then surged by 431.51% to $388000.0 in 2023, then plummeted by 34.79% to $253000.0 in 2024, then plummeted by 237.55% to -$348000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Change in Accured Expenses are -$348000.0 (Q4 2025), -$38000.0 (Q3 2025), and -$518000.0 (Q2 2025).